PRVB News and Press, Provention Bio Inc. From 03/31/22

On March 26th, Provention Bio announced that the FDA accepted the BLA submission of Teplizumab for the delay of type 1 diabetes (T1D) indication for at-risk individuals. The goal date for PDUFA is August 17th. Until then, there is no meaningful catalyst, meaning the stock could trade ...

Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 PR Newswire PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in h...

Clinical stage biopharmaceutical company, Provention Bio (NASDAQ:PRVB), announced on Monday that the U.S. Food and Drug Administration (FDA) accepted its resubmitted Biologics License Application (BLA) for experimental medication for diabetes, teplizumab. With the BLA, Provention (PRVB)seeks ...

Provention Bio, Inc. (PRVB) Q4 2021 Earnings Conference Call February 24, 2022, 08:00 AM ET Company Participants Robert Doody - VP, IR Ashleigh Palmer - Co-Founder, President, CEO Francisco Leon - Co-Founder & Chief Scientific Officer Jason Hoitt - Chief Commercial Officer Thierry Chauche...

Provention Bio press release (NASDAQ:PRVB): Q4 GAAP EPS of -$0.41 beats by $0.04. As of December 31, 2021, Provention had cash, cash equivalents and marketable securities of $127.1 million. Shares -2.5% PM. For further details see: Provention Bio GAAP EPS of -$0.41 beats by $0...

Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update -Company resubmits Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals to the U.S. Food and Drug Administ...

Provention Bio (NASDAQ:PRVB) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.46 (+20.7% Y/Y) and the consensus Revenue Estimate is $0.47M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 down...

The clinical-stage biopharmaceutical company, Provention Bio (NASDAQ:PRVB), is trading ~5% higher in the pre-market after the company announced the resubmission of its marketing application for experimental diabetes therapy teplizumab in the U.S. With the resubmission to the Food an...

Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL) PR Newswire RED BANK, N.J. , Feb. 22, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical ...

Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022 PR Newswire RED BANK, N.J. , Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preven...